In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.
Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O.
Laukkanen S, et al. Among authors: lohi o.
Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87.
Blood Cancer J. 2017.
PMID: 28885610
Free PMC article.
No abstract available.